Loading clinical trials...
Loading clinical trials...
An Open, Single-arm, Multi-center Exploratory Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer
Conditions
Interventions
Anlotinib Hydrochloride
Locations
1
China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Start Date
October 1, 2019
Primary Completion Date
August 31, 2020
Completion Date
August 31, 2022
Last Updated
October 1, 2019
Lead Sponsor
Nanfang Hospital, Southern Medical University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions